Madrigal Pharmaceuticals Inc
MDGL
188.81USD-8.49 (-4.30%)Delayed as of 28 Nov 2023, 01:05 pmWatchlist
Market Summary
USD188.81-8.49
Delayedas of 28 Nov 2023, 01:05 pm-4.30%
MDGL Stock Price
View Fullscreen
MDGL RSI Chart
MDGL Valuation
MDGL Price/Sales (Trailing)
MDGL Profitability
MDGL Fundamentals
MDGL Revenue
MDGL Earnings
Price Action
52 Week Range
57.21322.67
(Low)(High)
Last 7 days
3.8%
Last 30 days
63.9%
Last 90 days
9.9%
Trailing 12 Months
193.8%
How does MDGL drawdown profile look like?
MDGL Financial Health
MDGL Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2021 | 2.6M | 1.5M | 743.0K | 0 |
| 2020 | 9.9M | 8.1M | 6.1M | 4.3M |
| 2019 | 10.0M | 11.8M | 11.8M | 11.0M |
| 2018 | 1.2M | 2.3M | 4.9M | 7.7M |
| 2017 | 0 | 0 | 0 | 558.0K |
| 2016 | 0 | 0 | 0 | 0 |
| 2015 | 0 | 0 | 0 | 0 |
| 2014 | 0 | 0 | 0 | 0 |
| 2013 | 0 | 0 | 0 | 0 |
| 2012 | 0 | 0 | 0 | 0 |
| 2011 | 12.4M | 9.9M | 8.2M | 7.6M |
| 2010 | 111.9M | 79.5M | 47.2M | 14.8M |
| 2009 | 0 | 0 | 0 | 144.2M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for MDGL
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Nov 21, 2023 | baker bros. advisors lp | bought | 12,128,300 | 188 | 64,350 | - |
| Nov 20, 2023 | huntsman carole | acquired | - | - | 7,834 | chief commercial officer |
| Nov 20, 2023 | baker bros. advisors lp | bought | 3,846,580 | 185 | 20,709 | - |
| Nov 17, 2023 | baker bros. advisors lp | bought | 8,100,700 | 174 | 46,370 | - |
| Nov 15, 2023 | baker bros. advisors lp | bought | 2,461,720 | 161 | 15,199 | - |
| Nov 14, 2023 | baker bros. advisors lp | bought | 5,799,650 | 154 | 37,660 | - |
| Nov 14, 2023 | baker bros. advisors lp | bought | 5,347,840 | 156 | 34,188 | - |
| Nov 13, 2023 | baker bros. advisors lp | bought | 10,001,400 | 143 | 69,839 | - |
| Sep 11, 2023 | sibold william john | acquired | - | - | 50,000 | president and ceo |
| Jun 15, 2023 | daly james m | acquired | - | - | 1,198 | - |
Which funds bought or sold MDGL recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 18.47 | -2,147,240 | 6,406,920 | -% |
| Nov 22, 2023 | Verity Asset Management, Inc. | added | 36.67 | -61,737 | 392,409 | 0.29% |
| Nov 21, 2023 | COMERICA BANK | new | - | 4,131 | 4,131 | -% |
| Nov 16, 2023 | McIlrath & Eck, LLC | unchanged | - | -4,418 | 7,594 | -% |
| Nov 16, 2023 | Creative Planning | new | - | 302,887 | 302,887 | -% |
| Nov 15, 2023 | Tudor Investment Corp Et Al | added | 45.76 | -58,369 | 685,220 | 0.01% |
| Nov 15, 2023 | Edgestream Partners, L.P. | reduced | -39.03 | -364,825 | 228,845 | 0.02% |
| Nov 15, 2023 | Dana Investment Advisors, Inc. | new | - | 444,984 | 444,984 | 0.02% |
| Nov 15, 2023 | Capital Impact Advisors, LLC | unchanged | - | -181,729 | 312,380 | 0.52% |
| Nov 15, 2023 | JANE STREET GROUP, LLC | added | 157 | 5,806,980 | 15,098,500 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Madrigal Pharmaceuticals Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Nov 21, 2023 | baker bros. advisors lp | 9.99% | 1,987,702 | SC 13D/A | |
| Nov 13, 2023 | paulson & co. inc. | 5.1% | - | SC 13G | |
| Oct 10, 2023 | janus henderson group plc | 15.4% | 3,042,661 | SC 13G/A | |
| Oct 05, 2023 | baker bros. advisors lp | 9.99% | 2,015,760 | SC 13D/A | |
| Sep 08, 2023 | janus henderson group plc | 10.3% | 1,910,301 | SC 13G | |
| Aug 08, 2023 | baker bros. advisors lp | 8.4% | 1,545,113 | SC 13D/A | |
| Jun 20, 2023 | baker bros. advisors lp | 8.4% | 1,545,113 | SC 13D | |
| Feb 14, 2023 | baker bros. advisors lp | 9.0% | 1,545,113 | SC 13G/A | |
| Feb 14, 2023 | avoro capital advisors llc | 9.7% | 1,660,000 | SC 13G/A | |
| Feb 14, 2023 | deep track capital, lp | 0% | 0 | SC 13G/A |
Recent SEC filings of Madrigal Pharmaceuticals Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 22, 2023 | 3 | Insider Trading | |
| Nov 22, 2023 | 4 | Insider Trading | |
| Nov 21, 2023 | 4 | Insider Trading | |
| Nov 21, 2023 | 4 | Insider Trading | |
| Nov 21, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Nov 15, 2023 | 4 | Insider Trading | |
| Nov 15, 2023 | 4 | Insider Trading | |
| Nov 13, 2023 | SC 13G | Major Ownership Report | |
| Nov 06, 2023 | 10-Q | Quarterly Report | |
| Nov 06, 2023 | 8-K | Current Report |
Peers (Alternatives to Madrigal Pharmaceuticals Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 32.8B | - | 14.55% | 467931.97% | -3.8K | 218.4K | - | -102.45% |
MRNA | 29.6B | 10.7B | 8.07% | -55.95% | -8.54 | 2.78 | -53.67% | -129.46% |
ALNY | 20.0B | 1.7B | 4.90% | -25.16% | -39.17 | 11.59 | 79.37% | 56.87% |
BMRN | 16.7B | 2.3B | 9.83% | -8.58% | 113.5 | 7.22 | 15.05% | 75.21% |
INCY | 11.8B | 3.6B | 0.63% | -32.44% | 27.88 | 3.28 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 5.7B | 272.9M | 1.64% | -5.18% | -9.43 | 20.95 | 141.38% | 4.43% |
BBIO | 5.2B | - | 21.89% | 247.20% | -8.88 | 48.33 | 54.84% | -12.96% |
ACAD | 3.6B | 631.9M | 1.65% | 46.39% | -24.37 | 5.74 | 23.54% | 31.53% |
AXSM | 3.1B | 223.4M | 6.77% | 16.65% | -15.53 | 14.03 | - | -26.24% |
ARWR | 3.1B | 256.2M | 21.69% | -2.64% | -16.98 | 12 | 2.51% | -17.66% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 17.40% | -16.91% | 24.23 | 4.31 | 81.69% | -7.29% |
NVAX | 648.3M | 1.0B | -14.02% | -66.99% | -1.18 | 0.62 | -43.15% | 58.48% |
INO | 108.4M | 6.4M | 10.81% | -79.60% | -0.66 | 16.83 | -44.11% | 50.48% |
CRBP | 18.7M | - | -19.00% | 3569.57% | -0.39 | - | - | -13.74% |
IBIO | 8.0M | - | - | -82.21% | -0.12 | - | - | -29.23% |
Madrigal Pharmaceuticals Inc News
Latest updates
Financials for Madrigal Pharmaceuticals Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 | 2016Q3 |
| Revenue | -34.1% | 60,000 | 91,000 | 160,000 | 432,000 | 823,000 | 1,204,000 | 1,870,000 | 2,214,000 | 2,766,000 | 3,005,000 | 3,039,000 | 2,979,000 | 2,821,000 | 1,166,000 | 705,000 | 216,000 | 174,000 | 92,000 | 76,000 | 59,000 | 42,000 |
| Operating Expenses | 2.3% | 63,160,000 | 61,742,000 | 52,979,000 | 59,555,000 | 58,786,000 | 50,327,000 | 38,005,000 | 29,954,000 | 24,195,000 | 22,704,000 | 18,119,000 | 14,454,000 | 11,333,000 | 7,826,000 | 7,069,000 | 8,911,000 | - | - | - | - | - |
| S&GA Expenses | -18.0% | 8,287,000 | 10,110,000 | 7,209,000 | 6,126,000 | 5,494,000 | 5,639,000 | 4,605,000 | 5,044,000 | 4,748,000 | 7,110,000 | 5,746,000 | 5,583,000 | 5,122,000 | 2,717,000 | 1,871,000 | 2,399,000 | - | - | - | - | - |
| Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.4% | -63,100,000 | -61,651,000 | -52,546,000 | -59,123,000 | -57,963,000 | -49,023,000 | -36,135,000 | -27,740,000 | -21,429,000 | -19,699,000 | -15,080,000 | -11,475,000 | -8,512,000 | -6,460,000 | -6,364,000 | -8,445,000 | - | - | - | - | - |
| Net Income Margin | -107.2% | -318 | -153 | -83.49 | -46.72 | -27.96 | -16.68 | -10.65 | -7.62 | -5.74 | - | - | - | - | - | - | - | - | - | - | - | - |
| Free Cashflow | 2.7% | -45,606,000 | -46,883,000 | -43,473,000 | -54,957,000 | -47,853,000 | -24,265,000 | -30,820,000 | -12,416,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -21.3% | 238 | 302 | 332 | 363 | 159 | 216 | 223 | 273 | 305 | 328 | 310 | 287 | 340 | 388 | 411 | 442 | 456 | 470 | 480 | 485 | 490 |
| Current Assets | -21.9% | 235 | 302 | 331 | 361 | 157 | 215 | 221 | 272 | 303 | 326 | 308 | 285 | 338 | 387 | 409 | 440 | 455 | 469 | 478 | 485 | 489 |
| Cash Equivalents | -19.6% | 62.00 | 77.00 | 113 | 332 | 59.00 | 53.00 | 42.00 | 36.00 | 49.00 | 34.00 | 44.00 | 54.00 | 109 | 62.00 | 67.00 | 47.00 | 89.00 | 73.00 | 47.00 | 57.00 | 38.00 |
| Net PPE | 44.8% | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Liabilities | 8.4% | 216 | 199 | 182 | 165 | 148 | 133 | 77.00 | 77.00 | 70.00 | 57.00 | 49.00 | 47.00 | 50.00 | 45.00 | 26.00 | 25.00 | 16.00 | 13.00 | 11.00 | 8.00 | 7.00 |
| Current Liabilities | 0.0% | 100 | 100 | 98.00 | 116 | 99.00 | 84.00 | 77.00 | 77.00 | 69.00 | 57.00 | 49.00 | 47.00 | 49.00 | 45.00 | 26.00 | 25.00 | 15.00 | 12.00 | 10.00 | 8.00 | 7.00 |
| LT Debt, Non Current | 15.6% | 115 | 99.00 | 84.00 | 49.00 | 49.00 | 49.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | -78.5% | 22.00 | 104 | 150 | 197 | 11.00 | 84.00 | 146 | 196 | 235 | 271 | 261 | 240 | 290 | 343 | 385 | 417 | 440 | 457 | 469 | 477 | 483 |
| Retained Earnings | -8.8% | -1,224 | -1,125 | -1,039 | -962 | -876 | -795 | -724 | -667 | -602 | -539 | -478 | -425 | -366 | -308 | -259 | -223 | -195 | -174 | -154 | -139 | -127 |
| Additional Paid-In Capital | 1.4% | 1,246 | 1,229 | 1,190 | 1,160 | 888 | 880 | 871 | 863 | 838 | 810 | 739 | 665 | 656 | 650 | 644 | 640 | 636 | 631 | 623 | 617 | 611 |
| Shares Outstanding | 0.2% | 18.00 | 18.00 | 18.00 | 18.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 16.00 | 16.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -12.8% | -84,920 | -75,310 | -84,067 | -58,515 | -59,069 | -57,360 | -49,913 | -48,051 | -45,556 | -46,881 | -43,429 | -54,947 | -47,850 | -24,258 | -30,506 | -12,282 | -11,324 | -11,540 | -6,478 | -6,265 | -5,238 |
| Share Based Compensation | 15.4% | 12,660 | 10,973 | 11,250 | 8,082 | 8,122 | 7,944 | 7,477 | 6,356 | 6,242 | 8,179 | 6,096 | 5,134 | 5,061 | 5,689 | 4,846 | 4,032 | 4,950 | 7,755 | 6,022 | 5,119 | 4,976 |
| Cashflow From Investing | 1445.1% | 50,199 | -3,732 | -186,864 | 66,387 | 65,137 | 19,236 | 55,926 | 15,643 | 40,091 | -27,325 | -33,464 | -4,798 | 94,753 | 19,365 | 50,460 | -30,507 | 28,267 | 36,438 | -3,491 | 24,988 | -222,028 |
| Cashflow From Financing | -54.4% | 19,580 | 42,930 | 52,690 | 264,337 | - | 49,114 | - | 19,503 | 21,099 | 63,541 | 67,094 | 4,629 | 350 | 109 | - | - | 35.00 | 117 | 83.00 | 610 | 451 |
MDGL Income Statement
2023-09-30Condensed Consolidated Statements Of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenues: | ||||
| Total revenues | ||||
| Operating expenses: | ||||
| Research and development | 70,951 | 68,271 | 201,710 | 174,699 |
| General and administrative | 27,583 | 12,141 | 61,610 | 33,573 |
| Total operating expenses | 98,534 | 80,412 | 263,320 | 208,272 |
| Loss from operations | (98,534) | (80,412) | (263,320) | (208,272) |
| Interest income | 3,298 | 717 | 10,625 | 1,109 |
| Interest expense | (3,504) | (1,502) | (8,741) | (2,282) |
| Net loss | $ (98,740) | $ (81,197) | $ (261,436) | $ (209,445) |
| Net loss per common share: | ||||
| Basic net loss per common share | $ (5.34) | $ (4.75) | $ (14.27) | $ (12.25) |
| Diluted net loss per common share | $ (5.34) | $ (4.75) | $ (14.27) | $ (12.25) |
| Basic weighted average number of common shares outstanding | 18,476,414 | 17,103,395 | 18,326,154 | 17,103,395 |
| Diluted weighted average number of common shares outstanding | 18,476,414 | 17,103,395 | 18,326,154 | 17,103,395 |
MDGL Balance Sheet
2023-09-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 62,055 | $ 331,549 |
| Marketable securities | 170,296 | 27,225 |
| Prepaid expenses and other current assets | 3,118 | 2,595 |
| Total current assets | 235,469 | 361,369 |
| Property and equipment, net | 659 | 601 |
| Right-of-use asset | 1,836 | 602 |
| Total assets | 237,964 | 362,572 |
| Current liabilities: | ||
| Accounts payable | 16,542 | 23,831 |
| Accrued expenses | 82,610 | 91,461 |
| Lease liability | 513 | 602 |
| Total current liabilities | 99,665 | 115,894 |
| Long term liabilities: | ||
| Loan payable, net of discount | 114,727 | 49,289 |
| Lease liability | 1,323 | |
| Total long term liabilities | 116,050 | 49,289 |
| Total liabilities | 215,715 | 165,183 |
| Stockholders' equity: | ||
| Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at September 30, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | ||
| Common stock, par value $0.0001 per share authorized: 200,000,000 at September 30, 2023 and December 31, 2022; 18,494,192 and 18,102,523 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 2 | 2 |
| Additional paid-in-capital | 1,246,385 | 1,160,079 |
| Accumulated other comprehensive loss | (42) | (32) |
| Accumulated deficit | (1,224,096) | (962,660) |
| Total stockholders' equity | 22,249 | 197,389 |
| Total liabilities and stockholders' equity | $ 237,964 | $ 362,572 |
| Â WEBSITE | www.madrigalpharma.com |
|---|---|
| Â EMPLOYEES | 92 |